Novartis Home

At Novartis, we are reimagining medicine

Navigate Novartis

Patients & Caregivers
Healthcare Professionals
Media
Investors

Cell & Gene Therapy at Novartis

Our teams aim to deliver on the promise of cell and gene therapy for patients.

Novartis associates paint a wall of the new “relaxation room” in a orthopaedagogy day care facility

Community Partnership Day 2019

First launched in 1997, Community Partnership Day is an opportunity for associates around the world to give back to their local communities every year.

#NovartisCPD2019

Learn More

Child receiving child-friendly antimalarial in Kibera, Kenya.

World Malaria Day 2019

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.

Learn More

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

Media releases

Novartis Home

At Novartis, we are reimagining medicine

Cell & Gene Therapy at Novartis

Community Partnership Day 2019

World Malaria Day 2019

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event